Takumi Taniguchi1, Hiroko Kanakura, Ken Yamamoto. 1. Department of Emergency and Critical Care Medicine, School of Medicine, Kanazawa University, Kanazawa, Japan. taniyan@med.kanazawa-u.ac.jp
Abstract
OBJECTIVE: To clarify the effects of posttreatment with propofol administration on mortality rate and cytokine responses to endotoxin-induced shock in rats. DESIGN: Randomized prospective laboratory study. SETTING: University laboratory. SUBJECTS: Thirty-three male rats. INTERVENTIONS: Animals were randomly assigned to one of three groups (n = 11 per group): a) endotoxemic group, receiving intravenous Escherichia coli endotoxin (20 mg/kg over 2 mins); b) early posttreatment group, treated identically to the endotoxemic group with the additional administration of propofol (10 mg/kg bolus, followed by infusion at 10 mg x kg(-1) x hr(-1)) 1 hr after the injection of endotoxin; and c) late posttreatment group, treated identically to the endotoxemic group with the additional administration of propofol (10 mg/kg bolus, followed by infusion at 10 mg x kg(-1) x hr(-1)) 2 hrs after the injection of endotoxin. MEASUREMENTS AND MAIN RESULTS: Hemodynamics and arterial blood gases were recorded, and mortality rate and plasma cytokine concentrations were calculated for the 5-hr observation. The mortality rate 5 hrs after endotoxin injection was 73% for the endotoxic, 9% for the early posttreatment, and 36% for the late posttreatment groups. The mortality rate for the early posttreatment group was significantly lower than that for the other groups. The increases in plasma cytokine (tumor necrosis factor-alpha and interleukin-6 and -10) concentrations were less for the early posttreatment group than the other two groups. CONCLUSIONS: The early posttreatment of propofol after endotoxin injection drastically reduced the mortality rate of rats and attenuated their cytokine responses. Moreover, propofol attenuated the production of tumor necrosis factor-alpha. These findings suggest that propofol administration may be beneficial during sepsis.
OBJECTIVE: To clarify the effects of posttreatment with propofol administration on mortality rate and cytokine responses to endotoxin-induced shock in rats. DESIGN: Randomized prospective laboratory study. SETTING: University laboratory. SUBJECTS: Thirty-three male rats. INTERVENTIONS: Animals were randomly assigned to one of three groups (n = 11 per group): a) endotoxemic group, receiving intravenous Escherichia coli endotoxin (20 mg/kg over 2 mins); b) early posttreatment group, treated identically to the endotoxemic group with the additional administration of propofol (10 mg/kg bolus, followed by infusion at 10 mg x kg(-1) x hr(-1)) 1 hr after the injection of endotoxin; and c) late posttreatment group, treated identically to the endotoxemic group with the additional administration of propofol (10 mg/kg bolus, followed by infusion at 10 mg x kg(-1) x hr(-1)) 2 hrs after the injection of endotoxin. MEASUREMENTS AND MAIN RESULTS: Hemodynamics and arterial blood gases were recorded, and mortality rate and plasma cytokine concentrations were calculated for the 5-hr observation. The mortality rate 5 hrs after endotoxin injection was 73% for the endotoxic, 9% for the early posttreatment, and 36% for the late posttreatment groups. The mortality rate for the early posttreatment group was significantly lower than that for the other groups. The increases in plasma cytokine (tumor necrosis factor-alpha and interleukin-6 and -10) concentrations were less for the early posttreatment group than the other two groups. CONCLUSIONS: The early posttreatment of propofol after endotoxin injection drastically reduced the mortality rate of rats and attenuated their cytokine responses. Moreover, propofol attenuated the production of tumor necrosis factor-alpha. These findings suggest that propofol administration may be beneficial during sepsis.
Authors: Michael A Smith; Maho Hibino; Bonnie A Falcione; Katherine M Eichinger; Ravi Patel; Kerry M Empey Journal: Ann Pharmacother Date: 2013-11-04 Impact factor: 3.154
Authors: Marc P Steurer; Martina A Steurer; Werner Baulig; Tobias Piegeler; Martin Schläpfer; Donat R Spahn; Volkmar Falk; Pamela Dreessen; Oliver M Theusinger; Edith R Schmid; David Schwartz; Thomas A Neff; Beatrice Beck-Schimmer Journal: Crit Care Date: 2012-10-14 Impact factor: 9.097